Exit Survey of Women with HSDD Treated with Bremelanotide Demonstrated Meaningful Treatment Benefits
ACOG ePoster. Koochaki P. Apr 27, 2018; 211494; 28G
Patricia Koochaki
Patricia Koochaki
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
Introduction: Bremelanotide, an investigational new drug, demonstrated clinically meaningful improvements in desire and decrease in distress in premenopausal women with hypoactive sexual desire disorder (HSDD) in the phase 3 RECONNECT studies. Here we present outcomes from exit surveys completed by a subset of subjects from RECONNECT, with a focus on the meaningfulness of treatment benefit.

Methods: Study subjects were randomized to self-administer bremelanotide (1.75 mg) or placebo subcutaneously via auto-injector pen as desired prior to sexual activity for 24 weeks. Upon study completion, 242 women participated in a quantitative exit survey.

Results: Among subjects who completed the survey, mean(SD) duration of HSDD was 55.2(48.1) months; symptoms at baseline included decreased sexual interest and desire, decreased arousal, changes in sexual satisfaction/orgasm, and physical changes in lubrication. Overall meaningful benefit as determined using the exit survey was seen in 58.8% of the bremelanotide group and 27.1% of the placebo group (p<0.0001). The bremelanotide group reported a meaningful increase in sexual desire and responsiveness to their partners initiating sexual activity (51.0% and 53.9%, respectively) compared to placebo (20.7% and 25.7%, respectively; p<0.0001 for both). Treatment with bremelanotide was associated with significant improvement in sexual satisfaction (56.9% vs 25.7%; p<0.0001), and meaningful improvements in mental (52.0% vs 25.7%; p<0.0001) and physical (64.7% vs 21.4%; p<0.0001) arousal. Overall, 62.4% of participants rated their experience with the device as excellent or very good.

Conclusion/Implications: Women randomized to bremelanotide consistently reported meaningful treatment benefits compared to placebo, which reiterated the primary outcomes in the overall RECONNECT study population.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings